What this is
- How it works
- How it works isn't classified yet
- Tested for
- Androgenetic Alopecia (2 trials)
- Main trialPhase 2/3
- “The study is designed to validate efficacy and long term safety of PP405.”In the company’s words, NCT07819435 on ClinicalTrials.gov
Other drugs for Androgenetic Alopecia
- RitlecitinibPfizer · Phase 3
- VDPHL01Veradermics, Inc. · Phase 3
- OMA102EMS · Phase 3
- DA-001Applied Biology, Inc. · Phase 2/3
- DeuruxolitinibSun Pharma · Phase 3
- CKD-843Chong Kun Dang Pharmaceutical · Phase 3
Coming up2
- Sep 2027Phase 2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 2/3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 17 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07907783
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | Dec 2027 | Phase 2/3 Efficacy and Safety of PP405 in Adult Males | |
| Phase 2Recruiting | Sep 2027 | Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia | |
| Phase 2Completed | 16 Jul 2025 | Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026